AP Biosciences Inc
AP Biosciences Inc researches and develops protein and antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, an… Read more
AP Biosciences Inc (6945) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.063x
Based on the latest financial reports, AP Biosciences Inc (6945) has a cash flow conversion efficiency ratio of -0.063x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-84.46 Million) by net assets (NT$1.34 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
AP Biosciences Inc - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how AP Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
AP Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AP Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing ConST Instruments Technology Inc
SHE:300445
|
0.040x |
|
Shuifa Energas Gas Co Ltd
SHG:603318
|
-0.019x |
|
Pubmatic Inc
NASDAQ:PUBM
|
0.132x |
|
IS Dongseo
KO:010780
|
0.003x |
|
Meitav Trade Inv Ltd
TA:MTRD
|
N/A |
|
Jiangsu Fasten Co Ltd
SHE:000890
|
0.423x |
|
Akebia Therapeutics Inc
F:AX9
|
0.676x |
|
China Haisum Engineering Co Ltd
SHE:002116
|
0.046x |
Annual Cash Flow Conversion Efficiency for AP Biosciences Inc (2020–2024)
The table below shows the annual cash flow conversion efficiency of AP Biosciences Inc from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.62 Billion | NT$-357.88 Million | -0.221x | +41.90% |
| 2023-12-31 | NT$784.11 Million | NT$-297.62 Million | -0.380x | -51.10% |
| 2022-12-31 | NT$1.10 Billion | NT$-275.97 Million | -0.251x | +16.88% |
| 2021-12-31 | NT$558.20 Million | NT$-168.68 Million | -0.302x | -1039.68% |
| 2020-12-31 | NT$642.86K | NT$-17.05K | -0.027x | -- |